Annovis Bio, Inc. (ANVS)
Automate Your Wheel Strategy on ANVS
With Tiblio's Option Bot, you can configure your own wheel strategy including ANVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANVS
- Rev/Share 0.0
- Book/Share 1.3799
- PB 2.0871
- Debt/Equity 0.0
- CurrentRatio 10.6777
- ROIC -0.7793
- MktCap 56120256.0
- FreeCF/Share -465.4877
- PFCF -0.0069
- PE -0.0028
- Debt/Assets 0.0
- DivYield 0
- ROE -1880.9633
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ANVS | D. Boral Capital | Buy | Hold | -- | -- | Feb. 10, 2025 |
News
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Annovis to Host Webinar and Live Q&A on June 24, 2025
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.
Read More
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.
Read More
About Annovis Bio, Inc. (ANVS)
- IPO Date 2020-01-29
- Website https://www.annovisbio.com
- Industry Biotechnology
- CEO Dr. Maria L. Maccecchini Ph.D.
- Employees 8